Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
$8.19
$0.10(1.66%)
At close: 4:00 PM EST
$8.19
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$4.60 - $12.62
Previous CloseN/A
Volume37.28K
Average Volume (3M)77.23K
Market Cap
$147.79M
Enterprise Value$124.18M
Total Cash (Recent Filing)$20.61M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 27, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,489,515
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-5.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-143.39
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$15.50Price Target Upside89.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AMP Delivery Platform And Partnership PotentialThe Amphiphile delivery platform directs neoantigen peptides to lymph nodes to boost immune responses, offering a technology that could be licensed or partnered to generate new revenue streams.
ImmunogenicityELI-002 induced KRAS-specific T cell responses in nearly all evaluable pancreatic cancer patients in the randomized Phase 2 trial, supporting the vaccine's mechanism of action and biological activity.
Trial Design And Regulatory PathwayThe randomized adjuvant Phase 2 design with sufficient statistical power versus observation, combined with management's intent to pursue an End-of-Phase 2 meeting with the FDA, creates a clear pathway toward a pivotal Phase 3 if interim results are favorable.
Bears Say
Cash Runway RiskLimited cash reserves relative to ongoing development needs create a financing risk that could pressure the stock if additional funding becomes necessary before key clinical milestones.
Data Readout Delay And UncertaintyThe Phase 2 readout was postponed because the required number of relapse or death events has not been reached, prolonging uncertainty about clinical efficacy and next-step decisions.
Planned Capital Raise And Dilution RiskManagement's plan to raise capital to initiate a pivotal Phase 3 trial introduces potential dilution and investor uncertainty if Phase 2 results do not clearly support progression to a larger program.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $4.60 and its highest was $12.62 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $147.79M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Mar 27, 2026 which is in 56 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.12.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 17,489,515 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -0.871%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (89.26% Upside)
$15.50 (89.26% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
87.48%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$15.50
▲(89.26% Upside)
Technical Analysis
Compugen
―
Cassava Sciences
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
32.06% Insiders
2.94% Mutual Funds
0.19% Other Institutional Investors
62.32% Public Companies and
Individual Investors